ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1851

Healthcare Providers’ Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar

Chiara Gasteiger1, Maria Lobo2, Lun Shen Wong1, Rachel Murdoch1 and Nicola Dalbeth1, 1University of Auckland, Auckland, New Zealand, 2Department of Rheumatology, Te Toka Tumai Auckland, Auckland, New Zealand

Meeting: ACR Convergence 2023

Keywords: Biologicals, Health Services Research, Miscellaneous Rheumatic and Inflammatory Diseases

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1840–1861) Health Services Research Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Transitioning patients with rheumatic diseases to biosimilars has become common to reduce healthcare costs and improve patient access to biologic therapies. However, it is unclear how the transition process impacts healthcare providers at the frontline of the brand change. This study explores providers’ experiences of a nationwide mandatory brand change to an adalimumab biosimilar.

Methods: A nationwide online survey was conducted in Aotearoa New Zealand with rheumatologists, rheumatology nurses, and pharmacists. The transition was the first large-scale nationwide brand change for biosimilars and was anticipated to benefit >700 patients in the first year and reduce administrative burdens by extending authorization renewal durations. The transition occurred between March and September 2022, with data collected between November 2022 and February 2023. Survey items assessed satisfaction with logistics and supply, information and education, support, and administrative workload, on a 0-10 scale, with 10 indicating high satisfaction. Open-ended questions explored changes to workload and what did and did not go well during the transition.

Results: The sample (N = 164) consisted of rheumatologists (n = 39), rheumatology nurses (n = 16), and pharmacists (n = 109), yielding a response rate of 61%, 62%, and 3% for each practicing workforce. The mean [SD] overall satisfaction score with the transition was 5.7 [2.6]. Providers were the least satisfied with training for the biosimilar device (mean [SD] 3.7 [2.8]), information from government agencies (4.4 [2.7]), and administrative workload (4.6 [2.9]) during the transition. Satisfaction with adalimumab safety, efficacy, quality of the device, and the provision of sharps bins, alcohol wipes, and patient support was lower following the transition (p < .05 for all). Satisfaction with administrative workload (B = .37, p < .001) and training for the device (B = .20, p = .020) predicted overall satisfaction. Providers’ workload increased during the transition period due to additional patient counseling needs, navigating the initial authorization process, and sourcing resources and information. Participants reported that the transition was complicated by poorly implemented initial authorization processes and loss of the bio-originator patient support program. The citrate-free preservative and longer authorization duration after the transition were viewed positively.

Conclusion: Providers reported increased workload during the transition and less satisfaction with the biosimilar following the adalimumab transition. Provider experiences may be improved by ensuring training for the biosimilar device, maintaining a high-quality patient support program, and ensuring authorization processes function well throughout the transition period.


Disclosures: C. Gasteiger: None; M. Lobo: None; L. Wong: None; R. Murdoch: None; N. Dalbeth: Arthrosi, 2, AstraZeneca, 2, Dyve Biosciences, 2, Hikma, 6, Horizon, 2, JW Pharmaceutical Corporation, 2, LG, 2, Novartis, 6, Novotech, 5, PK Med, 2, Protalix, 2, PTC Therapeutics, 2, Selecta, 2, Unlocked Labs, 2.

To cite this abstract in AMA style:

Gasteiger C, Lobo M, Wong L, Murdoch R, Dalbeth N. Healthcare Providers’ Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/healthcare-providers-experiences-of-a-mandatory-nationwide-transition-to-an-adalimumab-biosimilar/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/healthcare-providers-experiences-of-a-mandatory-nationwide-transition-to-an-adalimumab-biosimilar/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology